Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097827 | 0.92 | HCRTR2 (0.45) | HCRTR2HCRTR1SMONAAA | |
| SCHEMBL3107028 | 0.78 | HCRTR1 (0.43) | HCRTR2HCRTR1SMO | |
| SCHEMBL2864662 | 0.77 | HCRTR2 (0.51) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL2878496 | 0.74 | HCRTR2 (0.53) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL8062603 | 0.73 | HCRTR1 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL1818884 | 0.70 | HCRTR2 (0.79) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1822065 | 0.70 | HCRTR2 (0.79) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL2858331 | 0.67 | HCRTR2 (0.61) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL16464605 | 0.64 | CSNK2A1 (0.46) | HCRTR2HCRTR1 | |
| SCHEMBL16465947 | 0.64 | HCRTR1 (1.00) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | claimed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | claimed |
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | claimed |
| US-8362009-B2 | Substituted diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2214676-B1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256121-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR2 1/4885HCRTR1 2/4885SMO 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.